340 related articles for article (PubMed ID: 2442078)
21. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
22. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
Kawakami K; Takahashi A; Yoshimoto T
No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
[TBL] [Abstract][Full Text] [Related]
23. New approaches to thrombolytic therapy.
Collen D; Lijnen HR
Arteriosclerosis; 1984; 4(6):579-85. PubMed ID: 6439177
[TBL] [Abstract][Full Text] [Related]
24. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Stump DC; Stassen JM; Demarsin E; Collen D
Blood; 1987 Feb; 69(2):592-6. PubMed ID: 3099862
[TBL] [Abstract][Full Text] [Related]
25. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
26. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
27. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
28. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
[TBL] [Abstract][Full Text] [Related]
29. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
30. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
Pannell R; Li S; Gurewich V
J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
[TBL] [Abstract][Full Text] [Related]
31. Activation of plasminogen by pro-urokinase. I. Mechanism.
Lijnen HR; Zamarron C; Blaber M; Winkler ME; Collen D
J Biol Chem; 1986 Jan; 261(3):1253-8. PubMed ID: 2935528
[TBL] [Abstract][Full Text] [Related]
32. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
33. Thrombolytic therapy in the eighties.
Verstraete M; Collen D
Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
[No Abstract] [Full Text] [Related]
34. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
Thorsen S
Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
[No Abstract] [Full Text] [Related]
35. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
Takada A; Shizume K; Cho M; Takada Y
Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
[TBL] [Abstract][Full Text] [Related]
36. Fibrinolytic effects of pro-urokinase combined with low-dose urokinase compared to high-dose urokinase in patients with acute myocardial infarction.
Pindur G; Koehler M; Sen S; Hermes R; Miyashita C; Wenzel E; Schieffer H
Thromb Res; 1992 Jul; 67(2):191-200. PubMed ID: 1279835
[TBL] [Abstract][Full Text] [Related]
37. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
38. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
39. Activation of the fibrinolytic system.
Robison AK; Collen D
Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
[TBL] [Abstract][Full Text] [Related]
40. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
Gurewich V; Hyde E; Lipinski B
Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
